Showing 6651-6660 of 7932 results for "".
- Novartis: New Data Show Cosentyx Has Durable Response Across Psoriatic Diseasehttps://practicaldermatology.com/news/novartis-new-data-show-cosentyx-has-durable-response-across-psoriatic-disease/2460068/A new comprehensive analysis shows the long-term efficacy and safety of secukinumab in multiple manifestations of psoriatic disease, including moderate-to-severe plaque-type, nail and palmoplantar psoriasis, psoriatic arthritis and ankylosing spondylitis. Data are derived from key Phase 3, random
- Aclaris Therapeutics: Positive 6-Month Results from Phase 2 Open-Label Trial of Topical ATI-502 in Androgenetic Alopeciahttps://practicaldermatology.com/news/aclaris-therapeutics-positive-6-month-results-from-phase-2-open-label-trial-of-topical-ati-502-in-androgenetic-alopecia/2460067/Results from a Phase 2 open-label clinical trial of ATI-502 (AGA-201), an investigational topical Janus Kinase (JAK) 1/3 inhibitor are promising for patients with androgenetic alopecia (AGA). Aclaris Therapeutics announced the findings and says 12-month data should be available by year’s en
- Lilly: 5-Year Sustained Efficacy and Safety Results for Taltz in Plaque Psoriasis at WCDhttps://practicaldermatology.com/news/lilly-5-year-sustained-efficacy-and-safety-results-for-taltz-in-plaque-psoriasis-at-wcd/2460066/Patients with moderate- to severe plaque psoriasis who continued to receive Taltz® (ixekizumab) maintained high levels of skin clearance with no unexpected safety outcomes for up to five years of treatment, according to new data Eli Lilly and Company is presenting at the World Congress of Der
- Gillette Skin Guard Reduces Razor Bumps by 60%https://practicaldermatology.com/news/gillette-skin-guard-reduces-razor-bumps-by-60/2460065/Gillette’s recently launched SkinGuard razor is helping men who are susceptible to razor bumps, also known as Pseudofolliculitis barbae or PFB, new research shows. Results from a recent clinical study from Wake Forest University revealed that the incidence of men’
- Data Show 2-Year Complete Response with AbbVie's Skyrizi: WCDhttps://practicaldermatology.com/news/data-show-2-year-complete-response-with-abbvies-skyrizi-wcd/2460064/New results presented by AbbVie show that a significant number of patients treated with Skyrizi™ (risankizumab) experienced complete skin clearance at week 94. These two-year results (up to 104 weeks) from the Phase 3 IMMhance study, evaluating the efficacy and safety of SKYRIZI in adu
- Skin Metabolomics: Estee Lauder Presents New Research at WCDhttps://practicaldermatology.com/news/skin-metabolomics-estee-lauder-presents-new-research-at-wcd/2460063/The Estée Lauder Companies Inc.Research & Development (R&D) team will present data focused on new findings in skin metabolomics, skin defense, ingredient science, and anti-aging research at the 2019 World Congress of Dermatology (WCD) in Milan, Italy from June 10 -15.
- Registration Open for Skin of Color Update Meetinghttps://practicaldermatology.com/news/registration-open-for-skin-of-color-update-meeting/2460060/The medical education event focused on the dermatologic treatment of skin of color has a new name. Skin of Color Update, previously the Skin of Color Seminar Series, provides dermatologists with evidence-based research and practical pearls in treating skin of color, including patients with multir
- Derm Residents Optimize Total Skin Exams Using Bioengineering Principleshttps://practicaldermatology.com/news/derm-residents-optimize-total-skin-exams-using-bioengineering-principles/2460058/Researchers at the Penn State Health Milton S. Hershey Medical Center are using engineering principles to improve the accuracy and efficiency of total body skin exams. There is no standardized method for performing a total body skin exam. D
- Pivotal Phase 3 Trials of Trifarotene in Patients with Moderate Facial and Truncal Acne Meet All Efficacy Endpointshttps://practicaldermatology.com/news/pivotal-phase-3-trials-of-trifarotene-in-patients-with-moderate-facial-and-truncal-acne-meet-all-efficacy-endpoints-2/2460056/Results from the pivotal Phase 3 PERFECT 1 and PERFECT 2 clinical trials of once-daily trifarotene 50 µg/g cream in patients with moderate acne on the face and trunk, published in the June issue of Journal of the American Academy of Dermatology, met all primary and secondary efficacy endpoi
- Water's Edge Dermatology Acquires Coast Dermatologyhttps://practicaldermatology.com/news/waters-edge-dermatology-acquires-coast-dermatology/2460055/Water's Edge Dermatology, a provider of comprehensive dermatology services through 37 Florida locations, has acquired a controlling interest in Coast Dermatology, a medical/cosmetic dermatology practice in Venice, Florida. Terms of the transaction were not disclosed. This transactio